Clinical trial · Interventional
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
NCT02038738CI-TRIAL-00013505unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Apudoma | Neuroendocrine Tumor | ALIAS | 0.90 |
| Carcinoid | Neuroendocrine Tumor | ALIAS | 0.90 |
| Carcinoid Tumor | Neuroendocrine Tumor | ALIAS | 0.90 |
| Islet Cell Tumor | Pancreatic Neuroendocrine Tumor | ALIAS | 0.90 |
| Neuroendocrine | — | UNRESOLVED | — |
| Neuroendocrine Cancer | Neuroendocrine Carcinoma | ALIAS | 0.90 |
| Neuroendocrine Carcinoma | Neuroendocrine Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Neuroendocrine Tumor | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Scan
- description
- We will perform 68Ga-DOTATATE PET scans on subjects.
- interventionNames
- Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
Primary outcomes (1)
- measure
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- timeFrame
- 5 years
Secondary outcomes (2)
- measure
- Number of lesions detected by 68Ga-DOTATATE compared to conventional imaging techniques
- timeFrame
- 5 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Known diagnosis of neuroendocrine tumor or suspected SSTR positive tumors by 111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen where clinically indicated * At least 18 years of age * Able to provide informed consent * Karnofsky performance score greater than 50 * Females of childbearing potential must have a negative pregnancy test at screening/baseline Exclusion Criteria: * Serum creatinine \> 2.0 mg/dL * Hepatic enzyme levels more than 3 times upper limit of normal * Known severe allergy or hypersensitivity to IV radiographic contrast * Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments * Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT, and MRI that will result * Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.) * Inability to complete the needed investigational standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Recognized concurrent active infection * Previous systemic or radiation treatment for another cancer of any type within the last 2 years * Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
References
Publications (0)
Data not yet available
No reference posted for this study.